ProShares UltraShort NASDAQ Biotechnology
19 hedge funds and large institutions have $46.6M invested in ProShares UltraShort NASDAQ Biotechnology in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.
492% more call options, than puts
Call options by funds: $24M | Put options by funds: $4.05M
138% more capital invested
Capital invested by funds: $19.6M → $46.6M (+$27M)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
0% more funds holding
Funds holding: 19 → 19 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$9.31M |
| 2 |
VF
Virtu Financial
New York
|
+$3.7M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.91M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$2.87M |
| 2 |
BHA
Beech Hill Advisors
New York
|
-$469K |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$443K |
| 4 |
ID
Integral Derivatives
New York
|
-$319K |
| 5 |
Morgan Stanley
New York
|
-$285K |
BIS Hedge Fund Activity: Q3 2015 in Review
19 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2015, worth a combined $46.6M — up 138% from $19.6M a quarter earlier.
Fund positioning in BIS was balanced in Q3 2015: 7 funds opened new positions, 7 closed out, 7 added to existing stakes and 3 trimmed.
The largest buyer was Ardsley Advisory Partners, adding an estimated $9.31M. The largest seller was Healthcare Value Capital, exiting entirely with an estimated $2.87M sold.
- 19 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $46.6M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2015, up 138% quarter-over-quarter.
- 7 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2015 and 7 closed out, a net change of 0 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2015 was Ardsley Advisory Partners, an estimated $9.31M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2015 was Healthcare Value Capital, an estimated $2.87M sold.
Based on aggregated 13F filings for Q3 2015.